Tradipitant in the Treatment of Gastroparesis: Vanda Presents Clinical Trial Results at DDW 2019

May 22, 2019 |

1 min read

Vanda Pharmaceuticals Inc. (VANDA) (Nasdaq: VNDA) today announced the results of the Phase II study of tradipitant in gastroparesis were presented at Digestive Disease Week® (DDW) 2019 in San Diego, CA.

WASHINGTON, May 22, 2019 /PRNewswire/ --Vanda Pharmaceuticals, Inc. (VANDA) (Nasdaq: VNDA) today announced the results of the Phase II study of tradipitant in gastroparesis were presented at Digestive Disease Week^® (DDW) 2019 in San Diego, CA.

For more information on DDW 2019, please refer to https://ddw.org/home.

About Vanda

Vanda is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.

Investor Contact:
Jim Kelly
Executive Vice President & Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com

Media Contacts:
AJ Jones II
Burson Cohn & Wolfe (BCW)
1110 Vermont Avenue, NW, Suite 1200
Washington, D.C. 20005
202-530-0400
pr@vandapharma.com

Elizabeth Van Every
Burson Cohn & Wolfe (BCW)
230 Park Avenue South
New York, NY 10003
212-614-3881
pr@vandapharma.com

View original content:http://www.prnewswire.com/news-releases/tradipitant-in-the-treatment-of-gastroparesis-vanda-presents-clinical-trial-results-at-ddw-2019-300855295.html